Most of the known regulatory mechanisms that curb inflammatory gene expression target pre-transcription-initiation steps, and evidence for post-initiation regulation of inflammatory gene expression remains scarce. We found that the transcriptional repressor Hes1 suppressed production of CXCL1, a chemokine that is crucial for recruiting neutrophils. Hes1 negatively regulated neutrophil recruitment in vivo in a manner that was dependent on macrophage-produced CXCL1, and it attenuated the severity of inflammatory arthritis. Mechanistically, inhibition of Cxcl1 expression by Hes1 did not involve modification of transcription initiation. Instead, Hes1 inhibited signal-induced recruitment of the positive transcription-elongation complex P-TEFb and thereby prevented phosphorylation of RNA polymerase II at Ser2 and productive elongation. Thus, our results identify Hes1 as a homeostatic suppressor of inflammatory responses that exerts its suppressive function by regulating transcription elongation.
Cytokines and chemokines recruit and activate specialized effector cells to sites of inflammation 1 . However, excessive production of inflammatory mediators leads to immune hyper-activation and tissue damage and contributes to the pathogenesis of inflammatory and autoimmune disorders such as rheumatoid arthritis (RA) 2 . Thus, expression of inflammatory mediators must be precisely controlled to avoid inappropriate inflammation and tissue damage. Many negative regulatory mechanisms have been described that curb inflammatory mediator production on multiple levels 3 . In particular, the complex nature of transcription makes it suitable for the precise and selective regulation that is essential for mounting the inflammatory responses most appropriate to given environmental cues 4 . The transcription of genes encoding inflammatory products can be negatively regulated via direct inhibition or epigenetic modifications that close chromatin structures 5 . Indeed, most of the described mechanisms for the regulation of genes encoding inflammatory products occur at or before transcriptional initiation via modulation of the recruitment of RNA polymerase II (Pol II) to transcription start sites (TSSs) 6 . However, advances in the investigation of the transcription cycle facilitated by high-throughput sequencing technology indicate that regulation at the post-initiation stage is extensive in scope and highly conserved across species from Drosophila to mammals 7, 8 .
Transcription elongation is a stepwise process during which Pol II ultimately synthesizes the full-length RNA transcript. During early elongation, Pol II escapes the promoter, transcribes a short RNA transcript and pauses at ~50 nucleotides downstream of the TSS. Pausing can be subsequently released by the transcription-elongation factor P-TEFb, which phosphorylates the regulatory C-terminal domain (CTD) of Pol II and facilitates productive elongation 7, 9 . Regulation of transcription elongation in the immune system has not been widely appreciated, but accumulating evidence suggests that such regulation is critical for fine tuning the expression of a subset of key inflammatory mediators [10] [11] [12] .
Hes1 ('hairy and enhancer of split 1') belongs to a family of basic helix-loop-helix DNA-binding proteins and is important for the development of multiple organs and cell types 13 . As a result, mice that are globally deficient in Hes1 are not viable and display multiple developmental defects 14 . Studies have shown that expression of Hes1 can be modulated by innate and inflammatory signals [15] [16] [17] and that Hes1, in turn, negatively regulates macrophage Toll-like receptor (TLR) responses 15 , which expands the role of Hes1 in immunoregulation beyond developmental processes 18 and suggests that Hes1 is involved in autoimmune and inflammatory disorders such as RA and systemic lupus erythematosus [19] [20] [21] [22] . However, the molecular mechanisms, transcription targets and physiological relevance of Hes1-mediated regulation of inflammation remain largely unknown.
We evaluated the role of Hes1 in gene regulation in primary macrophages and in inflammatory conditions in vivo. We found that Hes1 restrained inflammation and neutrophil-mediated responses by controlling production of macrophage-derived chemokines.
The inhibitory effects of Hes1 were highly restricted to a small subset of genes in the macrophage inflammatory transcriptome. Finally, we used one such Hes1-sensitive gene (Cxcl1) to assess the mechanistic basis of the non-conventional function of the repressor Hes1.
RESULTS

Hes1 and Hey1 regulate the inflammatory transcriptome
Inflammatory stimuli such as TLR ligands consistently induce expression of two members of the Hes family, Hes1 and Hey1, in macrophages 15 . To evaluate the effects of these two factors on inflammatory responses while circumventing their potential functional redundancy, we generated mice lacking both Hes1 and Hey1. Mice with global deletion of Hes1 are not viable 14 , whereas Hey1-deficient mice are phenotypically normal 23 . Thus, we generated Hey1 −/− Hes1 fl/fl Mx1-Cre mice, in which Hes1 flanked by loxP sites (Hes1 fl/fl ) is deleted by Cre recombinase expressed from the interferon-inducible Mx1 promoter. These mice were phenotypically indistinguishable from their Hey1 +/+ Hes1 fl/fl littermates after Hes1 deletion and did not display gross abnormalities up to 20 weeks of age. To identify Hes1-and Hey1-regulated inflammatory genes, we generated bone-marrowderived macrophages (BMDMs) from these mice and confirmed efficient deletion in Hes1-and Hey1-deficient BMDMs ( Supplementary  Fig. 1a ). Microarray analysis of lipopolysaccharide (LPS)-treated BMDMs revealed that, of hundreds of genes induced more than twofold by LPS in Hey1 +/+ Hes1 fl/fl cells, 25 genes were 'super-induced' in Hes1-and Hey1-deficient BMDMs relative to their expression in Hey1 +/+ Hes1 fl/fl cells ( Fig. 1a and Supplementary Fig. 1b) , which suggested that Hes1 and Hey1 inhibited inflammatory gene expression in a highly selective manner. Moreover, Hes1 and Hey1 regulated the expression of a small subset of LPS-suppressed genes (Supplementary Fig. 1c ). The super-induced genes encoded several key immunological and inflammatory effectors, including CXCL1, IL12p40 and IL-6 ( Supplementary Fig. 1b) . Super-induction of Cxcl1, Il12b and Il6 in Hes1-and Hey1-deficient BMDMs was confirmed by quantitative real-time PCR in multiple independent experiments (Fig. 1b,c) . We chose to focus on Cxcl1, as its regulation by Hes1 and Hey1 was among the most notable and reliable. Super-induction of Cxcl1 was also observed in Hes1-and Hey1-deficient BMDMs in response to other TLR ligands, such as the synthetic lipopeptide Pam 3 Cys, a TLR2 ligand, and the synthetic imidazoquinoline resiquimod (R-848), a TLR7 ligand (Supplementary Fig. 1d ), which indicated that the Hes1-and Hey1-mediated suppression of Cxcl1 was not specific to TLR4. In contrast to their regulation of Cxcl1, deficiency in Hes1 and Hey1 did not affect expression of the genes encoding the prototypical pro-inflammatory cytokines TNF and IL-1β (Fig. 1d) . Together these data indicated that Hes1 and Hey1 functioned as selective regulators of the macrophage inflammatory transcriptome.
Hes1, but not Hey1, suppresses Cxcl1 expression Given the gene-regulation patterns that we observed in Hes1-and Hey1-deficient BMDMs, we next sought to determine whether both Hes1 and Hey1 contributed to the suppression of Cxcl1 expression. In multiple experiments, we found that Cxcl1 induction was comparable in wild-type and Hey1 −/− BMDMs (Fig. 2a) , even in response to a relatively high dose (100 ng/ml) of LPS ( Supplementary  Fig. 2a) , which indicated that Hey1 deficiency alone was not sufficient to potentiate Cxcl1 expression. To investigate whether Hes1 suppresses Cxcl1 expression, we studied mice with inducible Hes1 deficiency alone (Hes1 fl/fl Mx1-Cre). Efficient deletion of Hes1 was verified in BMDMs at the level of both mRNA and protein ( Supplementary  Fig. 2b,c) . Following stimulation with LPS, Cxcl1 was super-induced in Hes1-deficient BMDMs in a pattern similar to that observed in Hes1-and Hey1-deficient cells (Fig. 2b) . The expression of CXCL1 protein was also higher in the supernatants of Hes1-deficient BMDMs than in that of Hes1-sufficient BMDMs (Fig. 2c) . Similar to the observations that we made with Hes1-and Hey1-deficient BMDMs, single deficiency in Hes1 did not affect expression of Tnf and Il1b (Fig. 2d) , and Hes1-mediated suppression of Cxcl1 was not specific to TLR4 signaling ( Supplementary Fig. 2d ). In contrast to the apparent lack of a role for Hey1 in the regulation of Cxcl1, deletion of either Hey1 or Hes1 led to super-induction of Il12b (Supplementary Fig. 2e ), which suggested that Il12b expression was inhibited by members of the Hes and Hey family via mechanisms that were distinct from those that regulated Cxcl1.
To rule out the possibility that our observations were linked to a specific deletion strategy, we generated two more mouse lines: Hes1 fl/fl Cre-ERT2 A r t i c l e s mice, in which gene deletion is induced by tamoxifen treatment, and mice with myeloid-cell-specific Hes1 deficiency, in which gene deletion is constitutive (Supplementary Fig. 3a,b,d ). Superinduction of Cxcl1 was also observed in macrophages derived from either Hes1 fl/fl Cre-ERT2 mice or mice with myeloid-cell-specific Hes1 deficiency, relative to its expression in cells from wild-type control mice (Supplementary Fig. 3c,e) ; this indicated that Hes1-mediated gene inhibition was a robust strain-independent phenomenon. Given that Mx1-Cre consistently achieved high deletion efficiency in macrophages, we proceeded with Hes1 fl/fl Mx1-Cre mice in most of the following experiments. To further confirm the observations reported above in a gain-of-function system, we overexpressed Hes1 in wild-type BMDMs by retroviral transduction (Fig. 2e) . Overexpression of Hes1 decreased the production of Cxcl1 mRNA and CXCL1 protein (Fig. 2f) , which indicated that exogenously introduced Hes1 was sufficient to mediate the inhibition. The suppressive effects of Hes1 on Cxcl1 expression were lost after deletion or mutation of key functional domains of Hes1 (refs. 13,24) ( Supplementary Fig. 4a-c) . In addition, reconstitution of Hes1-deficient BMDMs with Hes1 inhibited CXCL1 production (Fig. 2g) . Together these loss-of-function and gain-of-function findings supported the proposal of a critical regulatory role for Hes1 in macrophages as a selective suppressor of the expression of genes encoding inflammatory products.
Hes1 inhibits neutrophil recruitment in vivo
Having established that Hes1 negatively regulated Cxcl1 expression in vitro in cultured BMDMs, we sought to determine whether Hes1-mediated regulation also occurs in vivo. In a model of LPSinduced peritonitis, Hes1 deficiency in the hematopoietic compartment promoted the expression of Cxcl1 in peritoneal exudates without substantially altering Tnf or Il1b mRNA levels (Fig. 3a) . Given the importance of CXCL1 in the control of neutrophil recruitment during inflammatory responses 25 , we next investigated whether Hes1 deficiency affected neutrophil recruitment in vivo. In the peritonitis model, Hes1 deficiency resulted in an increase in the percentage and number of neutrophils in the peritoneum without affecting the total number of peritoneal cells or composition of other peritoneal populations ( Fig. 3b-d and Supplementary Fig. 5a-c) ; this indicated that Hes1 specifically suppressed neutrophil recruitment in vivo. The increased recruitment of neutrophils seen in Hes1-deficient mice was not a result of an intrinsically enhanced chemotactic capacity of neutrophils, as Hes1-deficient and wild-type neutrophils displayed similar motility in response to CXCL1 ( Supplementary  Fig. 5d-f) . Instead, macrophages in the peritoneal cavity of Hes1-deficient mice had higher CXCL1 expression than that of such cells in wild-type mice (Fig. 3e) , which suggested that Hes1 acted mainly to inhibit chemokine production by macrophages and thereby indirectly reduced neutrophil trafficking. That conclusion was further supported by the finding that adoptive transfer of Hes1-deficient macrophages into wild-type hosts led to more recruitment of wild-type neutrophils than did such transfer of Hes1-sufficient macrophages (Supplementary Fig. 5g ). These data established Hes1 as a selective suppressor of Cxcl1 expression in vitro and in vivo, with a non-redundant role in controlling neutrophil responses during inflammatory conditions. Neutrophils are required for the development of inflammatory arthritic symptoms in several experimental animal models, including arthritis induced by the transfer of serum from K/BxN mice 25, 26 . We investigated whether Hes1 deficiency regulated disease severity in serum-induced arthritis by monitoring joint swelling, a hallmark of acute inflammatory responses. Joint swelling was more severe in Hes1-deficient mice at multiple time points following the administration 
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A r t i c l e s of either a low dose or a high dose of serum (Fig. 4a) , which suggested that Hes1 deficiency exacerbated disease severity. Consistent with the joint-measurement results, histological analysis of ankle joints revealed heightened signs of inflammation and histological scores in Hes1-deficient mice relative to that of wild-type mice (Fig. 4b,c) . Collectively, these data indicated that the presence of Hes1 attenuated the development of inflammatory arthritis and suggested that Hes1 functioned as an endogenous brake of neutrophil-mediated tissue inflammation in a complex disease setting.
Hes1 represses Cxcl1 transcription
Next we sought to investigate the mechanisms by which Hes1 suppressed Cxcl1 expression. It is well established that TLR-induced activation of signaling cascades of the transcription factor NF-κB and mitogen-activated protein kinases (MAPKs) contribute to inflammatory gene activation 27 . We found that Hes1 deficiency did not affect TLR4-induced activation of NF-κB or of the MAPKs p38, Jnk or Erk (Fig. 5a) , which indicated that Hes1 did not inhibit Cxcl1 expression by altering TLR-induced canonical signaling events. Next, to assess whether Hes1 suppressed Cxcl1 transcription, we looked for Cxcl1 primary transcripts through the use of intronic PCR primers. Similar to the steady-state levels of Cxcl1 mRNA (Fig. 2b,c) , the levels of Cxcl1 primary transcripts were greater in Hes1-deficient BMDMs than in wild-type cells (Fig. 5b) , which indicated that Hes1-mediated suppression of Cxcl1 expression occurred at the transcriptional level. In contrast, Hes1 deficiency did not affect expression of Tnf primary transcripts (Fig. 5c) .
It has been shown that Hes1 acts via binding to conserved DNA sequences such as the N-box and E-box near gene promoters 13 . Analysis of the Cxcl1 core promoter region revealed two putative E-box sequences (Supplementary Fig. 6a) . Thus, we investigated whether Hes1 suppressed Cxcl1 transcription by acting through these putative E-boxes through the use of luciferase assays with a Cxcl1 reporter construct containing the E-box sites. Overexpression of Hes1 did not inhibit Cxcl1-promoter-driven luciferase activity in RAW264.7 mouse macrophages under either basal conditions or LPS-stimulated conditions (Supplementary Fig. 6b ), which indicated that the presence of E-box sequences was not sufficient for Hes1-mediated suppression of Cxcl1 transcription in this system. 
Hes1 suppresses transcription elongation of
A r t i c l e s
are probably not involved in the regulation of this gene. We investigated whether Hes1 targets specific steps of the transcription cycle to suppress Cxcl1 expression. First, we tested whether Hes1 suppressed the initiation if Cxcl1 transcription by using chromatin immunoprecipitation (ChIP) assays to assess binding of Pol II to the TSS region. Although minimal Pol II occupancy (<0.05% of input) was observed near the Cxcl1 TSS region at the basal state in resting BMDMs, occupancy by Pol II markedly increased following stimulation with LPS ( Fig. 6a) , which indicated that Cxcl1 fits the criteria of a 'non-paused' gene, with low levels of promoter-bound Pol II before activation and robust recruitment of Pol II for gene induction. In contrast, substantial Pol II occupancy was detected at baseline near the Tnf TSS region (Fig. 6b) , an observation consistent with the fact that Tnf has been reported to be a 'paused' gene 10 . Lack of Pol II occupancy at the silent locus encoding hemoglobin-β served as a negative control (Fig. 6c) . The level of Pol II occupancy near the Tnf TSS region did not differ in wild-type BMDMs versus Hes1-deficient BMDMs after LPS stimulation (Fig. 6b) , as predicted by the failure of Hes1 to regulate Tnf transcription (Fig. 5c) . In addition, Hes1 deficiency did not affect occupancy by Pol II near the Cxcl1 TSS region (Fig. 6a) despite the fact that Cxcl1 transcription was markedly enhanced in Hes1-deficient cells (Fig. 5b) ; this suggested that Hes1 did not regulate the initiation of Cxcl1 transcription and might instead target a post-initiation step (or more than one such step). In contrast to results obtained for Cxcl1, Hes1 deficiency was correlated with increased recruitment of Pol II to the TSS regions of Il6 and Il12b (Supplementary Fig. 6c ), which indicated that Hes1 inhibited initiation of the transcription of Il6 and Il12b. This result was consistent with the finding that Hes1 acts on promoter elements to repress these genes 15 and with the observation that these gene were sensitive to suppression by either Hes1 or Hey1 (Supplementary Fig. 2e ), indicative of a mechanism of inhibition that is probably distinct from that operating at Cxcl1. 
To gain further insight into post-initiation regulation, we used ChIP followed by deep sequencing (ChIP-seq) to assess genomewide distribution of Pol II before and after stimulation of LPS. Pol II occupancy was undetectable throughout the Cxcl1 locus under resting conditions in both wild-type BMDMs and Hes1-deficient BMDMs (Fig. 6d) , which was consistent with the results of the ChIP assays and confirmed that Cxcl1 is indeed a non-paused gene. Following LPS stimulation, Pol II occupancy of Cxcl1 markedly increased near the TSS and throughout the gene body in wild-type BMDMs (Fig. 6d) . Consistent with the ChIP data (Fig. 6a) , the recruitment of Pol II to an area near the Cxcl1 TSS did not substantially differ in wild-type BMDMs versus Hes1-deficient BMDMs (Fig. 6d) . Occupancy by Pol II throughout the Cxcl1 gene body was much greater in Hes1-deficient cells than in wild-type controls (Fig. 6d) , which indicated that Hes1 deficiency increased the amount of Pol II molecules available for transcription of Cxcl1; this would potentially account for its enhanced expression in Hes1-deficient cells. In contrast its occupancy of Cxcl1, substantial basal Pol II occupancy near the Tnf TSS was observed under unstimulated conditions (Fig. 6e) , consistent with published studies establishing Tnf as a paused gene 10 . Occupancy of the Tnf gene body by Pol II also markedly increased after LPS treatment, but this showed similar patterns in wild-type and Hes1-deficient BMDMs (Fig. 6e) , which suggested that Hes1 did not affect transcriptional elongation of this gene. Next, we used whole-genome Pol II distribution patterns (Supplementary Fig. 7a,b) to quantitatively analyze whether Hes1 deficiency altered transcription elongation by calculating pausing indices. The 'pausing index' for a given gene is the ratio of Pol II occupancy near the TSS region to Pol II occupancy in the gene-body region; therefore, it negatively correlates with productive elongation. Hes1 deficiency did not markedly change global pausing indices in untreated or LPS-stimulated conditions (Fig. 6f) . For LPS-induced genes, LPS stimulation led to reduced pausing indices (Fig. 6f) , in support of the hypothesis that LPS activates gene expression in part by promoting transcription elongation. For the group of super-induced genes (Fig. 1a) , Hes1 deficiency further lowered pausing indices under LPS-stimulated conditions (Fig. 6f) , which suggested that Hes1 deficiency promoted transcription elongation at select genes. Together these data suggested that Hes1 suppressed the elongation of Cxcl1 transcription and did so in a gene-specific manner.
To identify genes that, similar to Cxcl1, are the targets of Hes1-mediated suppression of transcriptional elongation, we performed bioinformatics analysis of the ChIP-seq data sets to calculate Pol II density throughout the gene-body regions. We compared Pol II occupancy in LPS-stimulated wild-type cells and Hes1-deficient cells and found that Hes1 deficiency resulted in enhanced occupancy by Pol II in the gene-body regions of nine genes (Supplementary Fig. 7c) . Notably, these nine genes included Cxcl1 and Dclbd2, which were among the super-induced genes in Hey1 −/− Hes1 fl/fl Mx1-Cre macrophages identified by microarray analysis (Fig. 1a and Supplementary  Fig. 1b) . Thus, the genome-wide ChIP-seq analysis confirmed our microarray data and helped to reveal the underlying mechanisms of Hes1-mediated selective gene regulation. 
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Hes1 targets P-TEFb to suppress productive elongation Next we investigated mechanisms by which Hes1 inhibits Pol IImediated elongation. The Pol II CTD contains a series of highly conserved heptapeptide repeats (YS 2 TPS 5 PS 7 ) with three serine residues at positions 2, 5 and 7 (subscripted), and phosphorylation of Ser2 in these repeats marks elongation-competent Pol II 9 . To investigate the possibility that Hes1 suppressed productive elongation by affecting the phosphorylation of Ser2, we measured Ser2-phosphorylated Pol II (S2P Pol II) at Cxcl1 by ChIP. Hes1 deficiency enhanced the occupancy of Cxcl1 by Ser2-phosphorylated Pol II at both the TSS and gene-body regions (Fig. 7a,b) , which suggested that Hes1 might suppress productive elongation of Cxcl1 by attenuating phosphorylation of Pol II at Ser2. Phosphorylation of Ser2 in the Pol II CTD is carried out by the P-TEFb heterodimeric complex, which comprises cyclin T1 and cyclin-dependent kinase 9 (CDK9) subunits 9 . During the transcription cycle, the recruitment of P-TEFb to genes to phosphorylate Pol II is a prerequisite for the release of Pol II into productive elongation 7 . We therefore investigated whether Hes1 inhibited occupancy by S2P Pol II by targeting recruitment of P-TEFb. ChIP showed greater occupancy by CDK9 at Cxcl1 in Hes1-deficient BMDMs than in wild-type cells (Fig. 7c,d ) in a manner that closely resembled regulation by S2P Pol II (Fig. 7a,b) . In contrast, Hes1 deficiency did not substantially affect the recruitment of CDK9 to Tnf in the presence or absence of LPS (Fig. 7e) , which suggested that the regulation of CDK9 occupancy by Hes1 was gene specific. To gain further insight into the potential mechanisms of Hes1-imposed regulation, we carried out genome-wide analysis of the distribution of CDK9 and Hes1 by ChIPseq analysis of primary macrophages. We found that Hes1 localized together with CDK9 near the Cxcl1 TSS region in LPS-activated BMDMs (Fig. 7f) , which suggested that Hes1 might regulate the transcription of specific genes by acting at CDK9-recruitment sites. As expected, the CDK inhibitor flavopiridol suppressed Cxcl1 mRNA in both wild-type BMDMs and Hes1-deficient BMDMs ( Supplementary  Fig. 8a) . Notably, Hes1 deficiency did not globally alter cellular levels of CDK9 protein (Supplementary Fig. 8b) .
In addition to its occupancy of Cxcl1, enhanced occupancy by S2P Pol II in Hes1-deficient BMDMs relative to that in wild-type BMDMs (Fig. 8a) was also observed at several other genes, including Gm15726 and Dcbld2, which harbored more Pol II in their gene-body regions in Hes-deficient BMDMs than in wild-type BMDMs, as revealed by ChIP-seq analysis of Pol II and computational analysis ( Supplementary  Fig. 7c ). Similar to Cxcl1, these genes also displayed greater, and even LPS-independent, occupancy by CDK9 in Hes1-deficient BMDMs BMDMs than in wild-type BMDMs (Fig. 8b) , which confirmed the robustness of our bioinformatics analysis for the identification of genes that are targets of Hes1-mediated regulation. In summary, these data demonstrated that Hes1 suppressed productive transcription of Cxcl1 by regulating the recruitment of P-TEFb and subsequent phosphorylation of Pol II at Ser2 (Supplementary Fig. 8c ).
DISCUSSION
Attenuation of the production of inflammatory mediators by endogenous inhibitory factors has been regarded as an important mechanism by which the body restrains inflammation and maintains immune homeostasis. However, most of these inhibitory events converge at the transcription initiation step and result in diminished assembly of the pre-initiation complex, as indicated by decreased Pol II occupancy near the target gene's TSS 28 . We found that the transcriptional repressor Hes1 selectively inhibited the expression of a subset of genes encoding inflammatory mediators, including CXCL1, a chemokine crucial for the recruitment of neutrophils to sites of inflammation. Notably, events such as TLR-induced signal transduction, activation of effector transcription factors responsible for Cxcl1 expression or its transcription initiation were unaffected by deletion of Hes1. Instead, Hes1 inhibited Cxcl1 transcription through the attenuation of Pol IImediated productive elongation by antagonizing the recruitment and, possibly, the activity of the Pol II CTD kinase P-TEFb, a tonic inhibition of elongation, which was relieved in Hes1-deficient macrophages.
Transcriptional elongation can be divided into two functional stages: early elongation and productive (late) elongation 7 . During early elongation, Pol II synthesizes short RNA transcripts and then, on many genes, pauses or stalls approximately 25-60 nucleotides downstream from TSS. Promoter-proximal pausing of Pol II has been postulated to represent a critical and rate-limiting step in transcription regulation for approximately half of all active Drosophila and mammalian genes 7 . In fact, several studies, including ours, have shown that the transcription of several key immunological genes, such as Tnf, is positively and negatively regulated at the early elongation step [10] [11] [12] . In contrast, Cxcl1 in resting macrophages lacked appreciable occupancy by Pol II, consistent with the proposal that Pol II recruitment and subsequent initiation are rate-limiting for gene activation. Nonetheless, the inhibitory effects of Hes1 affected mainly elongation, and the efficiency of late processive elongation, rather than pause-release, seemed to be attenuated. We are tempted to speculate that for the class of Cxcl1-like 'non-paused' genes, targeting of late elongation represents an effective way to regulate transcription rate beyond the point of initiation. Notably, Hes1 seemed to use different mechanisms to regulate different genes. Il6 and Il12b, for example, were also negatively regulated by Hes1, yet inhibition occurred at the transcription-initiation step and could have resulted from Hes1-mediated repression via promoter elements such as the N box or E box 15 .
In contrast to the wealth of knowledge on the regulation of promoter-proximal pausing, little is known about mechanisms that control late elongation. We found that Hes1 broadly inhibited the recruitment of CDK9 to the Cxcl1 locus and thereby attenuated phosphorylation of the Pol II CTD at Ser2. It remains unclear how Hes1 attenuated occupancy by P-TEFb in a gene-specific manner. P-TEFb is recruited to its target genes by transcription factors such as NF-κB and c-Myc 7,29 , but, given that most genes require P-TEFb for activation, additional regulators can clearly direct this kinase to promoters. Indeed, in our system, depletion of Hes1 had no effect on occupancy by the NF-κB subunit p65 at Cxcl1 (data not shown), which would suggest that Hes1 acts on as-yet-undetermined factors to inhibit the recruitment of CDK9. In fact, our ChIP-seq analysis of CDK9 and Hes1 revealed recruitment of Hes1 to the CDK9 sites near the Cxcl1 locus (also detected by ChIP-seq analysis of CDK9 in BMDMs under slightly different stimulation conditions 30 ). Colocalization of Hes1 and CDK9 would suggest that Hes1 might physically hinder excessive binding of CDK9, which would serve to constrain inflammatory response while still preserving signal-dependent transcription activation.
Transcriptional regulation at the post-initiation steps has been long appreciated in non-mammalian organisms such as Drosophila and has been appreciated more recently in mammalian systems 31 . Although the effect of elongation control in inflammation and immunity is only now being appreciated [10] [11] [12] , the data emerging from genomewide studies [32] [33] [34] [35] indicate it is likely that such a mode of regulation is broadly applicable to the immune system and might serve to fine-tune expression of key immunological effector molecules. The role we discovered for Hes1 provides an example of this, whereby npg targeting the transcription elongation of a chemokine-encoding gene yields important (patho)physiological consequences and affects inflammatory responses in vivo. The presence of Hes1 under homeostatic conditions was permissive for the robust production of cytokines critically involved in host defense against pathogens, such as TNF and IL-1β, while it limited CXCL1 production and paracrine signaling and thereby restrained the trafficking of neutrophils to inflammatory sites and tissue damage. It is plausible that dysregulation of the expression or function of Hes1 might contribute to heightened inflammation in human diseases such as asthma by promoting neutrophil recruitment. Conversely, enhancing the Hes1-mediated repressive pathway might represent a new therapeutic approach for selectively curbing of excessive inflammation with preservation of other aspects of immunity.
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